New i-On Skincare Creams Provide Clinically-Proven De-Ironizing Inducer Technology
DII technology is designed to remove excess iron from the skin and prevent free radicals from forming—which can cause the skin to age.
Tag: clinical trial
All
Popular
All
Latest
Long-Term Data Shows Sustained Skin Clearance in Psoriasis with FDA-Approved Biologic
Study results presented at EADV 2025 show nearly half of initial complete responders maintained clearance over four years.
All
Latest
A New Era for Fat-Based Injectables in Body Contouring
A new fat-based injectable is reshaping non-surgical body contouring. Plastic Surgery Practice examines the science and clinical adoption of alloClae with Tiger Aesthetics President Caroline Van Hove and Dr David Shafer.
Topical JAK Inhibitor Shows Itch Relief in Prurigo Nodularis Trial
Patients treated with a topical JAK inhibitor experienced significant reductions in itch as early as day 7 and greater treatment success by week 12.
Read More
Long-Term Study Suggests Extended Relief from Atopic Dermatitis After Topical Treatment
Data show most patients maintained mild disease for over two months without treatment following initial clearance in a 48-week extension trial.
Read More
Can Exosomes Heal Skin from Within? New Trial Puts Injectable to the Test
Researchers are evaluating a platelet-derived exosome product for its safety and possible regenerative impact on collagen and elastin.
Read More
Five-Year Data Show Low Complication Rates for Motiva Breast Implants
Midpoint data from a 10-year clinical study show low rates of reoperation, rupture, and capsular contracture in primary augmentation patients.
Read More
Galderma to Share New Data on Injectables and Weight Loss–Related Facial Changes
The company will present findings on Relfydess, Sculptra, and Restylane, along with results from an international survey on aesthetic impacts of medication-driven weight loss.Â
Read More
TYK2 Inhibitor Shows Promise for Moderate-to-Severe Psoriasis
A late-breaking presentation at AAD 2025 highlights the efficacy and safety of an oral TYK2 inhibitor, showing significant skin clearance in moderate-to-severe psoriasis patients.
Read More
Investigational Injectable Drug Demonstrates Efficacy in Localized Fat Reduction
Participants experienced an average reduction of 28.1% of subcutaneous fat volume compared with placebo.
Read More
Investigational Cream Improves Chronic Hand Eczema Symptoms
Late-breaking clinical trial data shows that a topical cream—currently under investigation in the US while approved in other markets—provides relief for patients with moderate to severe chronic hand eczema.
Read More
Bempikibart Shows Sustained Hair Regrowth in Alopecia Areata
Phase 2a trial data presented at AAD 2025 show bempikibart leads to sustained hair regrowth in severe alopecia areata, demonstrating for the first time an IL-7Rα antagonist approach.
Read More
FDA Approves Two New Hyaluronic Acid Fillers
One newly approved HA filler showed statistical superiority to Restylane-L at all measured time points over 12 months, while the other was superior at six and nine months despite 20% more Restylane-L being used.
Read More
Initial STP705 Phase I Trial Results Show Fat Reduction
Sirnaomics’ STP705 is a drug candidate for fat reduction in adults undergoing abdominoplasty. The STP705 Phase I trial results show signs of efficacy and safety.
Read More
Galderma Phase 3 Trial Shows Wrinkle Reducing Results
Galderma’s wrinkle treatment, RelabotulinumtoxinA, reduced wrinkles with minimal side effects in two phase III clinical studies.
Read More
Peer Reviewed Article Highlights Efficacy and Safety of Jeuveau in Patients with Skin of Color
A peer reviewed journal article highlighting the efficacy and safety of prabotulinumtoxinA (Jeuveau) for the treatment of moderate to severe glabellar lines, also known as frown lines between the eyes, in adult patients with Skin of Color (SOC), was published recently in Dermatologic Surgery, Evolus Inc announces in a media release.
Read More
Free Xtalks Webinar Dec 4: Developing a Digital Protocol for Dermatology Trials
Xtalks hosts Developing a Digital Protocol for Dermatology Trials: A Step-by-Step Guide to Optimizing Research for Patients and Clinicians, Friday December 4, 2020, at 10 am EST.
Read More
Galderma Releases Top-line Results from Phase 2 Clinical Dose-Escalating Study with Dysport (Azzalure)
Based on encouraging safety and long-term efficacy results of the Dysport study, and continued patient satisfaction, the company is evaluating future clinical studies.
Read More